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Most cancers are genetic disorders, i.e. they arise from an accumulation 
of mutations in genes involved in biological processes such as cell cycle 
control and DNA repair. This accumulation results in a ‘multiclonal’ 
tumour with increasing potential for cell proliferation, invasion and 
metastasis. The accumulated mutations are usually somatic in origin, 
and are therefore limited to the tumour tissue. Genetic changes within 
tumours are increasingly relevant to cancer screening, prognostication, 
treatment and monitoring, but are not discussed in this article. 
This review focuses on familial predisposition to cancer due to 
germline mutations. Clustering of cases of retinoblastoma provided 
the initial model for understanding familial cancers. Epidemiological 
studies suggested that retinoblastoma included a non-hereditary form 
and an autosomal dominant (AD) form. Knudson[1] hypothesised 
that retinoblastoma required two mutational events: in the non-
hereditary form both mutations occur in somatic cells, while in the 
AD form the first mutation is inherited in the germline (and therefore 
affects all cells), but the tumour is triggered by a ‘second hit’, which 
occurs somatically in a retinal cell.
The Knudson two-hit hypothesis explained why AD retino-
blastomas occur at a younger age, and may be bilateral or multifocal. 
Molecular verification of the hypothesis followed after retinoblastoma 
was linked to mutations in the RB1 gene and studies showed that 
carriers of a germline inactivating RB1 mutation had a 90% pene-
trance for retinoblastoma.[2] 
The development of more sophisticated genomic methods has 
allowed for identification of many more genes, conferring increased 
risk for a range of cancers. The affected genes typically have a role in 
control of cell replication (tumour-suppressor genes) and/or DNA 
repair. For the well-known genes, clinical studies have defined cancer 
risks better. Information about a particular gene is clinically useful if 
it leads to a clinical management guideline for pathogenic variants 
(mutations) in that gene. 
The focus of the current review is on the familial predisposition 
of two common neoplasms: breast cancer (BC) and colorectal 
cancer (CRC). BC occurs in ~12% of women and CRC in ~4% of 
the general population.[3] Familial clustering of cases of BC or CRC 
has long suggested a genetic basis. It is now clear that the genetics of 
familial BC and CRC are in principle similar to retinoblastoma, but 
include many more possible underlying causes. Some cases are due to 
co-occurrence of multiple environmental factors and low-penetrance 
genetic variants (and are considered multifactorial), whereas others 
are due to a mutation in one of several high-penetrance genes. The 
latter cause 10% of all cases of BC and CRC.[4,5]
Genetic testing for low-penetrance genes has low predictive value, 
even when combinations of genes are tested. In contrast, a positive 
genetic test for a moderate-to-high-penetrance gene may help refine 
clinical management, and allows identification of other at-risk family 
members who may benefit from cancer surveillance and preventive 
measures. 
Until recently, genetic testing was limited to a few individual 
genes, or even more narrowly to a few pathogenic variants known to 
be common in certain populations. The advent of next-generation 
sequencing (NGS) has allowed for simultaneous sequencing of NGS 
multigene panels that include many genes.[4,5] An updated approach 
to genetic counselling and testing for hereditary BC and CRC is 
discussed in light of these new gene panels.
Hereditary breast cancer 
Hereditary BCs can be divided into subgroups according to the lifetime 
risk of BC that each of the individual genes confer. The high-risk genes 
are known to cause a lifetime risk of ≥40% and the moderate-risk genes 
cause a lifetime risk of 20 - 39%.[3] 
BRCA1 and BRCA2 are the most common high-risk genes. 
Pathogenic variants in these genes are believed to cause 30 - 50% of all 
hereditary BCs. A pathogenic variant in one of these genes particularly 
predisposes to BC (lifetime risk of 39 - 87%) and ovarian cancer 
(lifetime risk of 16 - 63%).[3] The BRCA2 gene has also been associated 
with a smaller increased risk of certain other cancers (Table 1). 
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Two of the most common cancers are breast cancer and colorectal cancer. Up to 10% of cases of each are associated with a high risk of 
recurrence in an affected individual, or of occurrence in biological relatives. This results from the presence of an underlying mutation (or 
‘pathogenic variant’) in a high-penetrance gene. Such cases are typically associated with an autosomal dominant pattern of inheritance, 
although this may not be obvious in the family history. Genetic testing can identify many (but not all) of these cases, and should be offered 
to those whose family history or clinical features suggest a high risk. Although testing for certain risk genes (e.g. BRCA1 or BRCA2) has been 
available for years, the advent of next-generation sequencing ‘gene panels’ now allows for simultaneous testing of many more genes at lower 
cost. This allows for more frequent detection of pathogenic variants in underlying genes than in the past, but also makes interpretation more 
complex. An index of suspicion for genetic cancers and appropriate referral to a genetics health professional are increasingly important. 
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Testing for pathogenic variants in the BRCA1 and BRCA2 genes 
has been available for more than two decades, and variants in these 
genes are relatively well understood. Detection of a germline genetic 
variant may modify treatment of a person with cancer. A family 
member carrying a pathogenic variant may be offered intensive 
screening, risk-reducing surgery or other prophylactic measures, as 
recommended by evidence-based international guidelines, such as 
the US National Comprehensive Cancer Network (NCCN) and UK 
National Institute for Health and Care Excellence (NICE).[6,7] 
If no pathogenic variants are detected in BRCA1 or BRCA2, the BC 
may relate to a mutation in another gene associated with an increased 
risk of BC. Recent evidence suggests that other known genes account 
for up to 40% of cases, although this remains to be determined in 
local populations.[4] The following moderate- (to high) risk genes, 
for which international clinical management guidelines are available, 
account for most of these: CHEK2, PALB2 and ATM.[4] 
A small proportion (~3%) of hereditary BCs are due to genetic 
cancer syndromes that predispose to a broader range of cancers. 
These include hereditary diffuse gastric cancer syndrome, Li- 
Fraumeni syndrome, PTEN hamartoma tumour syndrome, and 
Peutz-Jeghers syndrome.[4] Further details regarding each of the 
genetic and syndromic causes are summarised in Table 1. 
Hereditary colorectal cancer
Hereditary CRC can be phenotypically divided into two types: 
non-polyposis associated and polyposis associated – the latter 
including polyps that are either adenomas or hamartomas. The 
cancer phenotype has traditionally been used to guide further genetic 
testing. Specific well-known hereditary CRC genes and syndromes 
are causative of each phenotype, as summarised in Table 2.[5] 
Lynch syndrome (previously referred to as hereditary non-
polypotic colorectal cancer (HNPCC) syndrome) is the most 
common cause of familial CRC, accounting for up to 6% of all cases. 
It is associated with a non-polyposis phenotype (i.e. no or few polyps 
detected on colonoscopy), and is caused by pathogenic variants in 
mismatch repair genes, e.g. MLH1, MSH2 (and the nearby EPCAM 
gene), MSH6 and PMS2.[5] Individuals with a mutation in one of these 
genes are also susceptible to extracolonic cancers (Table 2).[3,5] 
Pathogenic variants in Lynch syndrome genes cause abnormal 
repair of mismatches in DNA base pairs, leading to a phenomenon 
Table 1. Hereditary breast cancer genes/syndromes that have clinical guidelines[2,3,6,12] 
Gene Cancer syndrome/inheritance pattern
Lifetime risk of female 
BC up to 80 years, %
Key phenotypic features and predisposition 
to other cancers
ATM AD 17 - 52 Risk of BC is particularly increased
(˂50 years of age) 
Suspected elevated risk for pancreatic and 
prostate cancer 
BRCA1 Hereditary BC and ovarian cancer syndrome/AD 57 - 87 Triple-negative BCs
High risk for ovarian cancer (39 - 63%)
Slightly elevated risk for male BC and 
prostate cancer 
BRCA2 Hereditary BC and ovarian cancer syndrome/AD 38 - 84 High risk for ovarian cancer (16 - 27%)
Risk of melanoma, male BC (8.9%), prostate and 
pancreatic cancer 
CDH1 Hereditary diffuse gastric cancer syndrome/AD 42 Lobular BC almost always co-occurs with gastric 
cancers (56 - 80%)
CHEK2 AD 28 - 39 No conclusive evidence for associations with 
other cancers, although some other cancer risks 
suspected 
PALB2 AD 33 - 58 Later-onset BC and pancreatic cancer 
PTEN PTEN hamartoma syndromes (Cowden and 
Bannayan-Riley-Ruvalcaba)/AD, de novo: 11- 48%
25 - 85 Macrocephaly, penile freckling and fast-flow 
vascular anomalies
Risk of endometrial (28%), colorectal (9 - 
16%), thyroid and renal cancer, lipomas and 
gangliocytomas 
STK11 Peutz-Jeghers syndrome/AD, de novo: 45% 45 - 50 Pigmentation of lips, oral cavity and extremities, 
but it fades after puberty
Early-onset BC
High risk for ovarian cancer (18 - 21%)
Risk of hamartomas, lung, colorectal and 
pancreatic cancer 
TP53 Li-Fraumeni syndrome/AD 54 - 79 Early-onset cancers (usually childhood or young 
adulthood – ˂30 years)
Predisposes to all neoplasms 
Adrenocortical carcinoma, leukaemia, brain 
tumours, soft-tissue sarcoma, osteosarcoma BCs, 
usually ER+, PR+ and HER2+ 
BC = breast cancer; AD = autosomal dominant; ER = oestrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
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called ‘microsatellite instability’ (MSI) in tumour tissue. This is 
detectable with appropriate tumour DNA testing. Alternatively, 
tumour immunohistochemistry (IHC) may detect loss of staining for 
the protein products of one or more of the mismatch repair genes. 
Immunohistochemistry, often done together with MSI, may guide 
testing of the mismatch repair genes.[5] 
The revised Bethesda guidelines[8] were developed to determine if 
IHC and/or MSI should be performed on a CRC sample. If tumour 
testing is not easily accessible, the guidelines may help to determine 
whether an affected individual should be offered genetic testing of the 
mismatch repair genes. The criteria are as follows:
• CRC at <50 years of age 
• synchronous or metachronous CRC or other Lynch-related tumours 
at any age 
• CRC at <60 years of age, with tumour histology suggesting high 
MSI 
• CRC in ≥1 first-degree relative(s) with a Lynch-related tumour, 
1 diagnosed at <50 years of age
• CRC in ≥2 first- or second-degree relatives with Lynch-related 
tumours at any age.
The polyposis-associated syndromes are differentiated by polyp 
histology, the spectrum of extracolonic cancers and other clinical 
manifestations as detailed in Table 2. Each of these syndromes 
account for ˂1% of all CRC cases.[5] 
When to suspect hereditary breast or 
colorectal cancer[6,7,9-11]
If a person has a history of BC or CRC, further personal and family history 
should be obtained. The following characteristics significantly increase the 
likelihood of hereditary BC or CRC, and should prompt referral to a cancer 
genetics professional, usually a medical geneticist or genetic counsellor: 
• young age at diagnosis (<40 years for BC, <50 years for CRC)
• bilateral or multifocal BC, or BC in a male 
• CRCs or multiple colonic/endometrial polyps 
• anyone with BC, ovarian or pancreatic cancer who is of Afrikaner 
and/or Ashkenazi Jewish ancestry
• histopathological characteristics 
• triple-negative BC (<60 years of age) 
• CRC (or endometrial or ovarian cancer) with high MSI, or IHC 
indicating loss of expression of mismatch repair genes
• family history (or additional findings in the affected individual)
• pattern of cancer types that suggests a specific cancer syndrome 
(Tables 1 and 2), e.g. BC, ovarian cancer, prostate cancer and 
CRC, occurring in the same side of the family 
• less specific family history of BC or CRC, with at least 2 affected 
individuals. 
Genetic counselling and testing 
When offering a genetic test, pre- and post-test counselling is 
essential, due to the complexity of genetic information and potential 
Table 2. Hereditary colorectal cancer genes/syndromes that have clinical guidelines[3,5,9]
Gene 
Cancer syndrome/ 
inheritance pattern
Polyp burden  
and type
Lifetime risk of CRC 
up to 70 years, % 
(mean age of onset, 
years) 
Key phenotypic features and predisposition 
to other cancers
MLH1 
MSH2 
MSH6 
PMS2 
EPCAM
Lynch syndrome/AD <5
Adenoma
35 - 75 (27 - 46) Non-polyposis and usually MMR-deficient 
High risk for endometrial cancer (15 - 40%)
Risk for other cancers (not in MSH6 and PMS2 
carriers): ovarian (10 - 15%), small-bowel, brain, 
pancreatic and gastric cancers 
APC Familial adenomatous 
polyposis or attenuated 
familial adenomatous 
polyposis/AD
FAP >100 
AFAP 0 - 100 
Adenoma
FAP 93 - 100 (<35 - 40) 
AFAP 63 (54 - 62)
FAP: very young onset of adenomatous polyposis 
(7 - 36 years)
95% become neoplastic (by 35 years)
Soft-tissue tumours, osteomas and dental anomalies
Risk of small-bowel cancers (4 - 12%)  
Attenuated FAP: fewer polyps and later onset 
(usually >50 years) 
MUTYH MUTYH-associated 
polyposis/AR
0 - 100 
Adenoma
80 (biallelic) (50 - 58) Few adenomatous polyps that seem to follow AR 
pattern of inheritance (may be isolated case in the 
family)
Risk of gastrointestinal, duodenal, endometrial and 
thyroid cancers 
PTEN PTEN tumour 
hamartoma 
syndromes/AD
1 - 100 
Hamartoma
9 - 16 (44) Table 1 
STK11 Peutz-Jeghers 
syndrome/AD, 
de novo: 45%
1 - 100 
Hamartoma
39 - 57 (34 - 46) Table 1 
SMAD4 
BMPR1A
Juvenile polyposis 
syndrome/AD
5 - 200 
Hamartoma
20 - 50 (42 - 44) SMAD4-associated juvenile polyposis syndrome: 
hereditary haemorrhagic telangiectasia  
Risk of gastric (21%), pancreatic and small-bowel 
cancers 
CRC = colorectal cancer; AD = autosomal dominant; MMR = mismatch repair; FAP = familial adenomatous polyposis; AFAP = attenuated familial adenomatous polyposis;  
AR = autosomal recessive. 
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implications for the individual and other 
family members. 
Pre-test genetic counselling entails a 
‘risk estimation’ regarding the likelihood 
of detecting a pathogenic variant. A family 
history is taken and includes at least three 
generations and first-, second- and third-
degree relatives (Fig. 1). Cases of cancer 
are verified histologically if possible (more 
important for abdominal than breast 
tumours). If the likelihood of a genetic 
cause is high, the counsellor discusses the 
various genetic testing options, as well as the 
limitations, benefits and cost implications 
of each to promote informed decision-
making.[10,12] 
Patients undergoing genetic testing need 
to be aware of the possibility of finding a 
variant of uncertain significance (VUS), 
which has unclear health implications and 
does not warrant specific management. 
The more comprehensive the test, the 
more likely this finding is to occur. 
Screening and management should be 
based on the family history and other 
clinical risk factors, and the VUS should 
periodically be re-evaluated in the context 
of new information.[4,5,13]
If a multigene panel is offered, the possibi-
lity of a secondary finding of a pathogenic 
variant in a gene unrelated to the cancer being 
considered, needs to be discussed. The rare 
ethical dilemmas that may arise (as seen in 
the case example below) need to be kept in 
mind. If a secondary finding does occur, the 
implications and clinical management should 
be discussed appropriately.[13] 
Given the ‘actionable’ nature of cancer 
genetic information, interest in testing is 
high. However, testing is more difficult if 
the initial consultation is with an unaffected 
family member. Wherever possible, genetic 
testing should first be performed on an 
affected person, as this aids interpretation of 
positive and negative results.
Post-test genetic counselling is provided 
to discuss the implications of the result, 
whether positive or negative, for affected 
individuals and other family members. 
Implications for an affected 
individual
The finding may modify cancer treatment 
and/or increase risk of occurrence or 
recurrence of certain types of cancer. 
Associated risks and management should 
be discussed with the patient and manage-
ment altered according to available clinical 
guidelines. In the local setting, we use a 
combination of the NCCN and NICE guide-
lines.[6,7,9,11] 
If a pathogenic variant is identified, 
the discussion of risk should include 
consideration of both the variant and the 
family history, which may have a modifying 
effect.[4] 
A negative genetic test should be discussed 
in the context of the specific test and the 
family history. Even the most extensive test 
does not necessarily preclude the presence 
of hereditary cancer.[10,12] 
Implications for family members/
children
If a pathogenic variant is identified, there 
is up to a 50% chance of it being passed to 
a child. The patient’s siblings and extended 
family members are also at risk. Cascade 
testing to identify other carriers of the 
variant is important, as the carriers may 
qualify for specific surveillance and risk-
reducing options.[6,7,9-11] 
For genes associated with cancer in adult-
hood only, at-risk family members should be 
offered testing only when >18 years of age, 
when they are mature enough to make their 
own decisions. For earlier-onset conditions 
or in affected individuals, genetic testing is 
offered at a younger age.[12,14] 
Carriers of a pathogenic variant in certain 
genes are also at an increased risk of having 
children with specific severe autosomal 
recessive conditions, if their partner carries a 
variant in the same gene.[4] Testing of partners 
may therefore require consideration. 
Case – example 
Patient X, a 28-year-old man, was referred to 
the genetics division because of a diagnosis 
of early-onset CRC at the age of 23 years. 
His family history indicated that his mother 
was adopted and his father died from bone-
marrow cancer at a young age. There was no 
other known history of cancer. Based on the 
limited information available, a multigene 
panel for inherited cancer predisposition 
was requested and after pre-test counselling, 
the patient gave informed consent.
The results indicated a secondary finding, 
i.e. a pathogenic variant in the NBN gene. 
This gene is important in the repair of 
double-stranded breaks in DNA, and 
loss of function increases risks of certain 
cancers. However, it is unclear whether 
it significantly increases the risk of CRC. 
Nonetheless, it is well established that 
women with an NBN pathogenic variant 
have an up to 30% lifetime risk of BC, 
and guidelines recommend more intensive 
screening of carrier women. Certain studies 
have suggested an increased risk for other 
cancers; however, evidence is limited and 
management guidelines do not exist. Using 
current knowledge, this information was 
discussed with the patient and testing was 
offered to at-risk female family members. 
This result would not have been detected 
with a more limited genetic test. This 
information was useful in identifying females 
at increased risk of BC and informing them 
of the need for screening from a younger age. 
This should be balanced against the fact that 
it did not alter management in the proband, 
and that determination of an appropriate 
course of action required considerable time 
and attention from the clinical genetics team. 
Where possible, pre-test counselling 
with regard to all possible scenarios and 
anticipated outcomes should be done to 
avoid such scenarios going forward. 
Deciding between 
genetic testing options 
(single gene v. panel) 
When offering genetic testing, a genetics 
professional considers personal and familial 
characteristics, as well as technical and 
economic factors (Fig. 2).[12,14] 
Unknown
20/40
2005
• The proband is indicated by an arrow, and in 
this case only the maternal side of the family is depicted
• The pedigree is consistent with autosomal-dominant inheritance
• The case of ovarian cancer, together with the breast cancers, 
strongly suggests BRCA1/2 as a cause
• Without the ovarian cancer case, genetic testing is still indicated, 
but a multigene panel is worth considering
• If a pathogenic variant is detected in the proband, the sister’s 
19-year-old daughter is at near 50% risk, and is old enough to 
be oered testing
Died: 70 yo
Diabetes
Breast cancer
AOO: 50 yo
Died: 50 yo
Ovarian cancer
Died: 46 yo
2008
Breast cancer
38 yo
Breast cancer
19 yo 14 yo
Fig. 1. Interpreting a cancer pedigree. (yo = years old; AOO = age of onset.)
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In South Africa (SA), availability and cost 
are important determinants of access to 
genetic tests in the state and private sectors. 
The National Health Laboratory Service 
currently provides a very limited bouquet 
of tests. Medical insurance companies rarely 
reimburse genetic testing in the private 
sector. 
In some situations, it is reasonable first 
to test for founder mutations in the BRCA1, 
BRCA2 or MLH1 and MSH2 genes that 
are common in specific SA populations. 
These tests are relatively cheap (ZAR1 500 - 
3  000), but are population specific and do 
not exclude all pathogenic variants. 
Comprehensive testing is available locally 
for certain genes, especially BRCA1/2 and 
the Lynch syndrome genes, and typically 
cost ZAR6 000 - 12 000. 
Broader NGS gene panels, between 10 
and 100 genes, are increasingly available in 
laboratories based in SA and internationally. 
The cost may be no different to sequencing 
a single gene, i.e. the choice of test relates 
increasingly to patient and provider 
preference. In BC, first-line testing with a 
multigene panel is increasingly considered 
if the features do not strongly point to 
BRCA1/2. In CRC, use of a multigene panel 
is not always contingent on phenotyping 
results, as phenotyping is only useful for a 
subset of genes (MSI, IHC). 
Some difficulties with multigene panels 
have already been mentioned above, 
including the increased frequency of VUS 
and secondary findings, and the difficulty 
related to findings in genes lacking an 
established clinical management protocol.[6,9,13] 
Furthermore, genomic approaches are 
rapidly evolving, and the relevant genes and 
variants remain incompletely understood 
– especially in less-studied African popu-
lations. Therefore, a negative test is not 
definitive, and may warrant consideration 
for future repeat testing or further research. 
Conclusion
Up to 10% of BCs and CRCs are due to a 
single high-penetrance mutation in a family, 
with about half of these in the BRCA1/2 and 
Lynch syndrome genes, respectively. The 
increased availability of multigene panels 
allows testing of other genes, but increases 
the complexity of the information obtained. 
Detection of a genetic cause often modifies 
management of individuals with cancer, 
and is important to establish the risks for 
unaffected family members. Therefore, an 
index of suspicion for genetic cancers and 
appropriate referral to a genetics health 
professional are increasingly important. 
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